Difluoromethylornithine: The proof is in the polyamines

Cancer Prevention Research

Volumn 5, Issue 12, 2012, Pages 1341-1344

  Jeter, Joanne M ^a   Alberts, David S ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFLORNITHINE; TRIAMCINOLONE;

ARTICLE; CANCER PREVENTION; CELL PROLIFERATION; COLON ADENOMA; FOLLOW UP; HUMAN; NON MELANOMA SKIN CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; ULTRAVIOLET RADIATION;

EFLORNITHINE; FEMALE; HUMANS; MALE; SKIN NEOPLASMS;

EID: 84870675177     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-12-0429     Document Type: Article

References (36)

1. Housman T, Feldman S, Williford P, Fleischer AJ, Goldman N, Acostamadiedo J, et al. Skin cancer isamong themost costly of all cancers to treat for the Medicare population. J Am Acad Dermatol 2003;48:425-9. (Pubitemid 36337080)
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
3. Geller A, Miller D, Annas G, Demierre M, Gilchrest B, Koh H. Melanoma incidence and mortality among US whites, 1969-1999. JAMA 2002;288:1719-20.
4. Gerner E, Meyskens FL Jr. Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer 2004;4:781-92. (Pubitemid 39331150)
5. Pegg A. Polyamine metabolism and its importance in neoplastic growth and as a target for chemotherapy. Cancer Res 1988;48:759-74. (Pubitemid 18061860)
6. Meyskens F, Gerner E. Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Clin Cancer Res 1999;5:945-51. (Pubitemid 29233206)
7. Verma A, Lowe N, Boutwell R. Induction of mouse epidermal ornithine decarboxylase activity and DNA synthesis by ultraviolet light. Cancer Res 1979;39:1035-40. (Pubitemid 9135130)
8. Verma A, Shapas B, Rice H, Boutwell R. Correlation of the inhibition by retinoids of tumor promoter-induced mouse epidermal ornithine decarboxylase activity and of skin tumor promotion. Cancer Res 1979;39:419-25. (Pubitemid 9095903)
9. Abeloff M, Slavik M, Luk G, Griffin C, Hermann J, Blanc O, et al. Phase I trial and pharmacokinetic studies of alpha-difluoromethylornithine - an inhibitor of polyamine biosynthesis. J Clin Oncol 1984;2:124-30. (Pubitemid 14152455)
10. Abeloff MD, Rosen ST, Luk GD, Baylin SB, Zeltzman M, Sjoerdsma A. Phase II trials of alpha-difluoromethylornithine, an inhibitor of polyamine synthesis, in advanced small cell lung cancer and colon cancer. Cancer Treat Rep 1986;70:843-5.
11. Horn Y, Schecter PJ, Marton LJ. Phase I-II clinical trial with alpha-difluoromethylornithine - an inhibitor of polyamine biosynthesis. Eur J Cancer Clin Oncol 1987;23:1103-7. (Pubitemid 17112470)
12. O'Shaughnessy JA, Demers LM, Jones SE, Arseneau J, Khandelwal P, George T, et al. Alpha-difluoromethylornithine as treatment for metastatic breast cancer patients. Clin Cancer Res 1999;5:3438-44.
13. Levin VA, Prados MD, Yung WK, Gleason MJ, Ictech S, Malec M. Treatment of recurrent gliomas with eflornithine. J Natl Cancer Inst 1992;84:1432-7.
14. Levin VA, Uhm JH, Jaeckle KA, Choucair A, Flynn PJ, Yung WKA, et al. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N′-(2-chloroethyl)-N0- cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. Clin Cancer Res 2000;6:3878-84.
15. Prados MD, Wara WM, Sneed PK, McDermott M, Chang SM, Rabbitt J, et al. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2001;49:71-7. (Pubitemid 32041278)
16. Bachmann A, Geerts D, Sholler G. Neuroblastoma: ornithine decarboxylase and polyamines are novel targets for therapeutic intervention. Pediatric Cancer 2012;1:91-103.
17. Creaven PJ, Pendyala L, Petrelli NJ. Evaluation of alpha- difluoromethylornithine as a potential chemopreventive agent: tolerance to daily oral administration in humans. Cancer Epidemiol Biomarkers Prev 1993;2:243-7.
18. Love RR, Carbone PP, Verma AK, Gilmore D, Carey P, Tutsch KD, et al. Randomized phase I chemoprevention dose-seeking study of alpha- difluoromethylornithine. J Natl Cancer Inst 1993;85:732-7. (Pubitemid 23133595)
19. Fabian CJ, Kimler BF, Brady DA, Mayo MS, Chang CH, Ferraro JA, et al. A phase II breast cancer chemoprevention trial of oral alpha- difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers. Clin Cancer Res 2002;8:3105-17. (Pubitemid 35155020)
20. Vlastos AT, West LA, Atkinson EN, Boiko I, Malpica A, Hong WK, et al. Results of a phase II double-blinded randomized clinical trial of difluoromethylornithine for cervical intraepithelial neoplasia grades 2 to 3. Clin Cancer Res 2005;11:390-6. (Pubitemid 40075819)
21. Messing E, Kim KM, Sharkey F, Schultz M, Parnes H, Kim D, et al. Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer. J Urol 2006;176:500-4. (Pubitemid 43949406)
22. Simoneau AR, Gerner EW, Nagle R, Ziogas A, Fujikawa-Brooks S, Yerushalmi H, et al. The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial. Cancer Epidemiol Biomarkers Prev 2008;17:292-9. (Pubitemid 351272778)
23. Meyskens FL Jr, Gerner E, Emerson S, Pelot D, Durbin T, Doyle K, et al. Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention. J Natl Cancer Inst 1998;90:1212-8. (Pubitemid 28407087)
24. Carbone PP, Pirsch JD, Thomas JP, Douglas JA, Verma AK, Larson PO, et al. Phase I chemoprevention study of difluoromethylornithine in subjects with organ transplants. Cancer Epidemiol Biomarkers Prev 2001;10:657-61. (Pubitemid 32703200)
25. Meyskens FL Jr, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res 2008;1:32-8.
26. Sinicrope F, Broaddus R, Joshi N, Gerner E, Half E, Kirsch I, et al. Evaluation of difluoromethylornithine for the chemoprevention of Barrett's esophagus and mucosal dysplasia. Cancer Prev Res 2011;4:829.
27. Alberts DS, Dorr RT, Einspahr JG, Aickin M, Saboda K, Xu MJ, et al. Chemoprevention of human actinic keratoses by topical 2-(difluoromethyl)-dl- ornithine. Cancer Epidemiol Biomarkers Prev 2000;9:1281-6. (Pubitemid 32044795)
28. Einspahr JG, Nelson M, Saboda K, Warneke J, Bowden GT, Alberts DS. Modulation of biologic endpoints by topical difluoromethylornithine (DFMO), in subjects at high-risk for nonmelanoma skin cancer. Clin Cancer Res 2002;8:149-55. (Pubitemid 34101471)
29. Bartels P, Yozwiak M, Einspahr J, Saboda K, Liu Y, Brooks C, et al. Chemopreventive efficacy of topical difluoromethylornithine and/or triamcinolone in the treatment of actinic keratoses analyzed by karyometry. Anal Quant Cytol Histol 2009;31:355-66.
30. Bailey HH, Kim K, Verma AK, Sielaff K, Larson PO, Snow S, et al. A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin cancer. Cancer Prev Res 2010;3:35-47.
31. Kreul S, Havighurst T, Kim K, Mendonca E, Wood G, Snow S, et al. A phase III skin cancer chemoprevention study of DFMO: long-term follow-up of skin cancer events and toxicity. Cancer Prev Res 2012;5:1368-74.
32. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003;361:296.
33. Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, et al. Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 2007;99:272-82. (Pubitemid 47073490)
34. Kraemer K, DiGiovanna J, Moshell A, Tarone R, Peck G. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 1988;318:1633.
35. Vogel V, Costantino J, Wickerham D, Cronin W, Cecchini R, Atkins J, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-41.
36. Bresalier R, Sandler R, Quan H, Bolognese J, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092.